Background: Icrucumab and ramucirumab are recombinant human IgG1 monoclonal antibodies that bind VEGF receptors 1 and 2 (VEGFR-1 and -2), respectively. This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan.
Patients And Methods: Eligible patients were randomly assigned to receive mFOLFOX-6 alone (mFOLFOX-6) or in combination with ramucirumab 8 mg/kg IV (RAM+mFOLFOX-6) or icrucumab 15 mg/kg IV (ICR+mFOLFOX-6) every 2 weeks. Randomization was stratified by prior bevacizumab therapy. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, safety, and PK.
Results: In total, 158 patients were randomized, but only 153 received treatment (49 on mFOLFOX-6, 52 on RAM+mFOLFOX-6, and 52 on ICR+mFOLFOX-6). Median PFS was 18.4 weeks on mFOLFOX-6, 21.4 weeks on RAM+mFOLFOX-6, and 15.9 weeks on ICR+mFOLFOX-6 (RAM+mFOLFOX-6 versus mFOLFOX-6, stratified hazard ratio [HR] 1.116 [95% CI 0.713-1.745], P = 0.623; ICR+mFOLFOX-6 versus mFOLFOX-6, stratified HR 1.603 [95% CI 1.011-2.543], P = 0.044). Median survival was 53.6 weeks on mFOLFOX-6, 41.7 weeks on RAM+mFOLFOX-6, and 42.0 weeks on ICR+mFOLFOX-6. The most frequent adverse events reported on the ramucirumab arm (RAM+mFOLFOX-6) were fatigue, nausea, and peripheral sensory neuropathy; those on the icrucumab arm (ICR+mFOLFOX-6) were fatigue, diarrhea, and peripheral sensory neuropathy. Grade ≥3 serious adverse events occurred at comparable frequency across arms.
Conclusions: In this study population, combining ramucirumab or icrucumab with mFOLFOX-6 did not achieve the predetermined improvement in PFS.
Clinicaltrialsgov: NCT01111604.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdw412 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Total neoadjuvant therapy followed by total mesorectal excision for rectal cancer in older patients real world data and proof of concept.
Front Surg
November 2024
General Surgery Unit, Ospedale Santa Maria Delle Croci - AUSL Romagna, Ravenna, Italy.
Background: Rectal cancer (RC) commonly affects older patients. Total Neoadjuvant Therapy (TNT) has been introduced to improve local and systemic control of RC. The aim was to present real-world data of older patients receiving TNT followed by surgery after a frailty assessment and verify feasibility and safety of this approach.
View Article and Find Full Text PDFmFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.
BMC Cancer
March 2024
Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea.
Background: High-risk stage III colon cancer has a considerably poorer prognosis than stage II and low-risk stage III colon cancers. Nevertheless, most guidelines recommend similar adjuvant treatment approaches for all these stages despite the dearth of research focusing on high-risk stage III colon cancer and the potential for improved prognosis with intensive adjuvant treatment. Given the the proven efficacy of triplet chemotherapy in metastatic colorectal cancer treatment, the goal of this study is to evaluate the oncologic efficacy and safety of mFOLFIRINOX in comparison to those of the current standard of care, mFOLFOX 6, as an adjuvant treatment for patients diagnosed with high-risk stage III colon cancer after radical resection.
View Article and Find Full Text PDFPredictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial.
Front Oncol
May 2023
Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Introduction: Angiopoetin-2 (Ang-2) is a key mediator of tumour angiogenesis. When upregulated it is associated with tumour progression and poor prognosis. Anti-vascular endothelial growth factor (VEGF) therapy has been widely used in the treatment of metastatic colorectal cancer (mCRC).
View Article and Find Full Text PDFPreoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
BMC Cancer
May 2023
Department of Surgical Oncology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Article Synopsis
- Total neoadjuvant therapy (TNT) is being explored as a treatment option for locally advanced rectal cancer (LARC) to find a better alternative to traditional preoperative chemoradiotherapy (CRT).
- The study involves 30 high-risk LARC patients receiving a specific CRT regimen involving radiation and chemotherapy drugs like tegafur/uracil and irinotecan, followed by additional chemotherapy before surgery.
- The trial aims to assess the safety and feasibility of this new treatment approach, particularly in light of previous concerns over severe adverse events linked to similar regimens.
Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer.
Int J Colorectal Dis
April 2023
Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou, No. 5, Fuxing St., Guishan Dist., Taoyuan, 333, Taiwan.
Article Synopsis
- The study examined the effectiveness, safety, and mid-term outcomes of using short-course radiotherapy (SCRT) combined with oxaliplatin-based chemotherapy in patients with locally advanced rectal cancer (LARC).
- Out of 64 patients treated, a significant number responded well to the treatment, with a high rate of sphincter preservation observed during surgeries and minimal severe complications.
- After about 32 months of follow-up, most patients showed good overall survival and disease-free rates, indicating that this treatment approach is both safe and effective for downstaging tumors in LARC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!